Treatment of Factor XIII Deficiency with Cryoprecipitate

Summary

In in vitro and in vivo investigations of two patients with congenital factor XIII-deficiency it was demonstrated that cryoprecipitate contains a high factor XIII-activity. Cryoprecipitate in small amounts, given as intravenous injections every 3 or 4 weeks seems to be useful as a prophylactic treatment of patients with severe haemorrhagic due to factor XHI-deficiency.

• References

• 1 Amris C.J, Hilden M. To be published 1968
• 2 Amris C.J, Baneh L. A Case of Fibrin-Stabilizing Factor (FSF) Deficiency. Thrombos. Diathes. haemorrh. (Stuttg.) 1965; 14: 332-340
• 3 Gronberg S, Beifrage S, Nilsson I.M. Fibrinogen-Transmitted Hepatitis. Lancet 1963; I: 967-969
• 4 Hilden M, Amris C.J, Starup J. The Haemostatic Mechanism in Oral Contraception. Acta obstet gynec. scand 1967; 46: 562-571
• 5 Josso F, Petrova M, Ménaché D, Sizonenho P. Durée de vie du facteur stabilisant de la fibrine (facteur XIII). Incidences thérapeutiques. Transfusion 1966; 9: 343-346
• 6 Pool J.G, Shannon A.E. Simple production of high AHG concentration in a closed bag system. Fed. Proc 1965; 24: 512
• 7 Ratnojf O.D, Steinberg A.G. Inheritance of Fibrin-Stabilising-Factor Deficiency. Lancet. Jan 1968; 6: 25-26